Lineage Cell Therapeutics (LCTX) Income towards Parent Company (2010 - 2026)

Lineage Cell Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$19.3 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 183.83% year-over-year to -$19.3 million in Q1 2026; TTM through Mar 2026 was -$66.5 million, a 253.25% decrease from a year earlier, with the FY2025 full-year figure at -$63.4 million, down 241.01% from the prior year.
• Income towards Parent Company fell to -$19.3 million in Q1 2026 per LCTX's latest filing, from -$5.8 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$3.0 million in Q3 2024 and bottomed at -$22.5 million in Q2 2025.
• The 5-year median for Income towards Parent Company is -$6.3 million (2022), against an average of -$8.2 million.
• Across the five-year window, Income towards Parent Company jumped 77.43% in 2022 and sank 528.02% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$6.3 million in 2022, then rose by 25.42% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then slumped by 79.11% to -$5.8 million in 2025, then sank by 232.06% to -$19.3 million in 2026.
• Per Business Quant, the three latest LCTX Income towards Parent Company figures stand at -$19.3 million (Q1 2026), -$5.8 million (Q4 2025), and -$18.8 million (Q3 2025).